VPC-3033

• UNSPSC Description:

  VPC-3033 is an androgen receptor antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC50: 0.625-2.5 μM), can effectively inhibit androgen receptor transcriptional activity (IC50=0.3 μM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002)[1].

• Target Antigen:

  Androgen Receptor

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/vpc-3033.html

• Smiles:

  O=C1C2=C(/C(C3=C1C=CC=C3)=C\C4=CC(O)=CC=C4)C=CC=C2

• Molecular Weight:

  298.33

• References & Citations:

  [1]Li H, et al. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer[J]. Molecular cancer therapeutics, 2013, 12(11): 2425-2435.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  110763-24-1